Drugs / Non-immunogenic recombinant staphylokinase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06362746 | May 2024 → Jun 2028 expected | pulmonary embolism | Supergene, LLC | Recruiting | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Non-immunogenic recombinant staphylokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06362746 ↗ |